Intravenous iron: A useful therapeutic tool but not a panacea

American Journal of Hematology

Volumn 83, Issue 7, 2008, Pages 521-523

  Katodritou, Eirini ^a,b   Verrou, Evgenia ^a   Zervas, Konstantinos ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; HEMOSIDERIN; HEPCIDIN; IRON; IRON DEXTRAN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TRANSFERRIN;

ANEMIA; BACTEREMIA; CARDIOTOXICITY; CELL SURVIVAL; CHEST TIGHTNESS; DISEASE ASSOCIATION; DRUG EFFICACY; EDITORIAL; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HUMAN; HYPOTENSION; IRON DEFICIENCY; IRON DEPLETION; LOW BACK PAIN; MYALGIA; NEOPLASM; PERIORBITAL EDEMA; PRIORITY JOURNAL; TACHYCARDIA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; WHEEZING;

ANEMIA; HUMANS; INJECTIONS, INTRAVENOUS; IRON;

EID: 45749127928     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21189     Document Type: Editorial

References (42)

1. Goodnough L. Erythropoietin and iron-restricted erythropoiesis. Exp Hematol 2007;35:167-172.
2. Krause A, Neitz S, Magert H, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480:147-150.
3. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-7810.
4. Fleming R, Sly W. Hepcidin: A putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA 2001;98:8160-8162.
5. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing internalization. Science 2004;306:2090-2093.
6. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-78.
7. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995;26:41-46.
8. Fishbane S, Ungureanu VD, Maesaka J, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996;28:529-534.
9. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
10. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-242.
11. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 2007;21:627-632.
12. Auerbach M, Coyne D, Ballard H. Intravenous iron: From anathema to standard care. Am J Hematol 2008 [Epub ahead of print].
13. Auerbach M. Clinical update: Intravenous iron for anemia. Lancet 2007;369:1502-1504.
14. Rizzo JD, Somerfield MR, Hagerty KL, et al. American Society of Clinical Oncology/American Society of Hematology 2007. Clinical practice guideline update on the use of epoetin and darbepoetin. J Clin Oncol 2007;26:132-149.
15. Beguin Y. Intravenous iron and recombinant human erythropoietin in cancer patients. J Clin Oncol 2005;23:651-652.
16. Bastit L, Vanderbroek A, Altintas S, Gaede B, Pinter T, Suto TS, Mossman TW, Smith KE, Vasteenkiste JF. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-1618.
17. Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Blanchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619-1625.
18. Cavill I. Erythropoiesis and iron. Best Pract Res Clin Hematol 2002;15:399-409.
19. Coyne D. Iron indices: What do they really mean? Kidney Int 2006;69:4-8.
20. Weiss G, Gordeuk VR. Benefits and risks of iron therapy for chronic anaemias. Eur J Clin Invest 2005;35:36-45.
21. Huang X. Iron overload and its association with cancer risk in humans: Evidence for iron as a carcinogenic metal. Mutat Res 2003;533:153-171.
22. Bailie GR. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005;20:1443-1449.
23. Chertow GM, Mason PD, Vaage-Nielsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-382.
24. Beamish MR, Davies AG, Eakins JD, et al. The measurement of reticuloendothelial iron release using iron-dextran. Br J Haematol 1971;21:617-622.
25. Collins HL. The role of iron in infections with intracellular bacteria. Immunol Lett 2003;85:193-195.
26. Nairz M, Theurl I, Ludwiczek S, et al. The coordinated regulation of iron homeostasis in murine macrophages limits the availability of iron for intracellular salmonella typhimurium. Am J Hematol 2007;82:559.
27. Korbsrisate S, Amornrit W, Chitchumroonchokchai C, Lertmemongkolchai G. Iron overload host cells promote burkholderia pseudomallei infection. Am J Hematol 2007;82:601.
28. Drakesmith H, Eddowes L, Townsend A. Investigating the dependency of HIV-1 replication in macrophages on cellular iron. Am J Hematol 2007;82:509-510.
29. Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 2002;57:457-461.
30. Cavill I, Auerbach M, Bailie G, et al. Iron and the anaemia of chronic disease: A review and strategic recommendations. Curr Med Res Opin 2006;22:731-737.
31. Hershko C. Iron loading and its clinical implications. Am J Hematol, DOI 10.1002.
32. Scheiber-Mojdehkar B, Ternes N, Steinkellner H, et al. Intravenous iron preparations redox-active iron and oxitative stress S. Am J Hematol 2007;82:601.
33. Anderson GJ. Mechanism of iron loading and toxicity. Am J Hematol, DOI 10.1002.
34. Sengölge G, Hörl WH, Sunder-Plassmann G. Intravenous iron therapy: Well-tolerated, yet not harmless. Eur J Clin Invest 2005;35:46-51.
35. Kooistra MP, Kersting S, Gosriwatana I, et al. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002;33:36-41.
36. Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in hemodialysis patients. Nephrol Dial Transplant 2001;16:1416-1423.
37. Fishbane S, Galgano S, Langley R, et al. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997;52:217-222.
38. Wish JB. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006;1:4-8.
39. Katodritou E, Zervas K, Speletas M, et al. Hypochromic erythrocytes (%): A reliable marker of recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with multiple myeloma and lymphoma. Ann Hematol 2007;86:369-376.
40. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 2006;1(suppl 1):9-18.
41. National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(suppl 3):16-145.
42. Fishbane S, Kalantar-Zadeh K, Nissenson AR. Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dial 2004;17:336-341.